Literature DB >> 11260358

The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies.

J N Pennefather1, W A Lau, F Mitchelson, S Ventura.   

Abstract

1. We review literature demonstrating (a) the presence and (b) the actions of substances that mediate or modify neuroeffector transmission to the smooth muscle of the prostrate stroma of a number of species including man. 2. In all species studied prostatic stroma, but not secretory acini, receives rich noradrenergic innervation. Stimulation of these nerves causes contractions of prostate smooth muscle that are inhibited by guanethidine and by alpha1-adrenoceptor antagonists that probably act at the alpha1L-adrenoceptor. Such actions underlie the clinical use of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia (BPH). 3. Acetylcholinesterase-positive nerves innervate prostatic stroma as well as epithelium. Atropine reduces nerve-mediated contractions of stromal muscle in the rat, guinea-pig and rabbit. M1, M2 and M3 muscarinic receptors have been implicated in eliciting or facilitating contraction in the prostate from guinea-pig, dog and rat, respectively. 4. Adenine nucleotides and nucleosides, nitric oxide (NO), opioids, neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) may act as co-transmitters or modulators in autonomic effector nerves supplying prostate stroma. Adenosine inhibits neurotransmission to the rat prostate, and NO is inhibitory in prostate from human, rat, rabbit, pig and dog. The activity of peptides present in the relatively sparse sensory innervation of the prostate exhibits species variation, but, when effective, calcitonin gene-related peptide is inhibitory while tachykinins are stimulant. The roles of NPY and VIP in modulating stromal contractility remain unclear. 5. Taken together the current literature indicates that, in addition to noradrenaline, other neurotransmitters and neuromodulators may regulate the tone of prostatic smooth muscle. Whether drugs that mimic or modify their actions might be useful in providing symptomatic relief of the urinary symptoms associated with BPH remains to be established.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11260358     DOI: 10.1046/j.1365-2680.2000.00195.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  25 in total

Review 1.  Advances in the design and synthesis of prazosin derivatives over the last ten years.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Expert Opin Ther Targets       Date:  2011-12-13       Impact factor: 6.902

2.  Receptor-coupled, DAG-gated Ca2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells.

Authors:  V Sydorenko; Y Shuba; S Thebault; M Roudbaraki; G Lepage; N Prevarskaya; R Skryma
Journal:  J Physiol       Date:  2003-05-01       Impact factor: 5.182

Review 3.  Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms.

Authors:  Catherine A Thomas; Yao-Chi Chuang; Antonella Giannantoni; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

4.  The effect of histamine on field-stimulated contractions of the guinea-pig prostate.

Authors:  Karen P Kerr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-28       Impact factor: 3.000

5.  A temporal and spatial map of axons in developing mouse prostate.

Authors:  Anne E Turco; Mark T Cadena; Helen L Zhang; Jaskiran K Sandhu; Steven R Oakes; Thrishna Chathurvedula; Richard E Peterson; Janet R Keast; Chad M Vezina
Journal:  Histochem Cell Biol       Date:  2019-04-11       Impact factor: 4.304

6.  Postnatal androgen deprivation dissociates the development of smooth muscle innervation from functional neurotransmission in mouse vas deferens.

Authors:  J A Brock; D J Handelsman; J R Keast
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

7.  [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

Authors:  H Tezval; A S Merseburger; M Seidler; J Serth; M A Kuczyk; M Oelke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

8.  Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia.

Authors:  Dong Soo Park; Taek Woo Cho; Yong Kyu Lee; Young Tae Lee; Young Kwon Hong; Woong Ki Jang
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

Review 9.  Muscarinic acetylcholine receptor subtypes in the male reproductive tract: expression and function in rat efferent ductules and epididymis.

Authors:  Maria Christina W Avellar; Erica R Siu; Fabiana Yasuhara; Elisabeth Maróstica; Catarina S Porto
Journal:  J Mol Neurosci       Date:  2009-08-20       Impact factor: 3.444

Review 10.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.